Sadly, the majority of patients relapse and die, largely due to liver relapse. The chemotherapy options have been outlined above and there are no particularly encouraging new agents that are working their way through the development arena at present. Chemotherapy is never curative in this situation and its use should therefore be weighed and considered against the possible benefits; once again it’s the quality of life versus any perceived increase in length of life that has to be weighed.
Palliation of the dying patient is concentrated on pain control and then taking individual symptoms as they arise and treating on their own merits.
